The CMS has completed work on a long-awaited rule overhauling the way prescription drugs are purchased for Medicaid beneficiaries. The regulation has been submitted to the Office of Management and Budget for review.
An Abbott spokesman said Thursday that the company is not preparing to buy rival St. Jude Medical, a medical-device company, for $25 billion as reported by the Financial Times.
Massachusetts has introduced legislation to require pricing transparency and allow some price caps. Six other states are following, all while Congress acknowledges that there's a problem but has yet to do anything about it.
Amgen has won approval for the second medicine in a new class of biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades.
Biosimilar drugs will carry a four-letter suffix on the nonproprietary names they share with brand-name biologic drugs, the Food and Drug Administration announced Thursday. It's a move that could determine how lower-cost alternatives compete against their original counterparts.
Danish pharmaceutical giant Novo Nordisk said Wednesday that it has begun Phase III clinical trials of an oral version to its diabetes treatment candidate semaglutide.
Drugmaker Pfizer says it's received the final regulatory approvals for its $15.23 billion purchase of the injectable drug and infusion devicemaker Hospira, and says the deal will close in early September. The FTC has ordered Pfizer to sell four drugs in order to preserve competition.
Inovalon, a publicly traded healthcare analytics company, has entered into a definitive agreement to acquire healthcare consulting firm Avalere Health.
The threat of a looming “post-antibiotic era” has been detailed for years in media reports, but the Centers for Disease Control and Prevention says the nation has finally reached that tipping point.
United Therapeutics Corp. recently sold a record-setting $350 million voucher for fast-track Food and Drug Administration review to AbbVie. The secondary market for the vouchers highlights the industry's growing thirst to get to market with the next potential blockbuster therapy.
The Food and Drug Administration's recent approval of Addyi, the first drug to increase sexual desire in women, could lead to some new and complicated conversations in doctors' offices across the country.
Regardless of political affiliation, Americans strongly support government action to control prescription drug costs, according to a poll released Thursday.